EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis
Ortiz-Maldonado, V., Presa, M., Tejado, N., Pardo Millan, C., Martín-Escudero, V., Oyagüez, I., Martín García-Sancho, A.
Published in Value in health (01.12.2023)
Published in Value in health (01.12.2023)
Get full text
Journal Article
CO76 Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
Córdoba, R, López-Corral, L, Presa, M, Martín-Escudero, V, Casado, MÁ, Pardo Millan, C
Published in Value in health (01.12.2022)
Published in Value in health (01.12.2022)
Get full text
Journal Article